AU2003250935A8 - Bile acid derivatives as agonists of the farnesoid x receptor - Google Patents

Bile acid derivatives as agonists of the farnesoid x receptor

Info

Publication number
AU2003250935A8
AU2003250935A8 AU2003250935A AU2003250935A AU2003250935A8 AU 2003250935 A8 AU2003250935 A8 AU 2003250935A8 AU 2003250935 A AU2003250935 A AU 2003250935A AU 2003250935 A AU2003250935 A AU 2003250935A AU 2003250935 A8 AU2003250935 A8 AU 2003250935A8
Authority
AU
Australia
Prior art keywords
farnesoid
agonists
receptor
acid derivatives
bile acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250935A
Other versions
AU2003250935A1 (en
Inventor
Roberto Pellicciari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2003250935A8 publication Critical patent/AU2003250935A8/en
Publication of AU2003250935A1 publication Critical patent/AU2003250935A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
AU2003250935A 2002-07-12 2003-07-11 Bile acid derivatives as agonists of the farnesoid x receptor Abandoned AU2003250935A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2002MI001532A ITMI20021532A1 (en) 2002-07-12 2002-07-12 CHEMICAL COMPOUNDS
ITMI2002A001532 2002-07-12
PCT/EP2003/007512 WO2004007521A2 (en) 2002-07-12 2003-07-11 Bile acid derivatives as agonists of the farnesoid x receptor

Publications (2)

Publication Number Publication Date
AU2003250935A8 true AU2003250935A8 (en) 2004-02-02
AU2003250935A1 AU2003250935A1 (en) 2004-02-02

Family

ID=30012506

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250935A Abandoned AU2003250935A1 (en) 2002-07-12 2003-07-11 Bile acid derivatives as agonists of the farnesoid x receptor

Country Status (3)

Country Link
AU (1) AU2003250935A1 (en)
IT (1) ITMI20021532A1 (en)
WO (1) WO2004007521A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2440680C (en) 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr
EP1568706A1 (en) 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
JP5094384B2 (en) 2004-03-12 2012-12-12 インターセプト ファーマシューティカルズ， インコーポレイテッド Treatment of fibrosis using FXR ligands
US10987362B2 (en) 2004-03-12 2021-04-27 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using FXR ligands
US7618956B2 (en) 2005-05-31 2009-11-17 The Gillette Company Reduction of hair growth
AU2008209566C1 (en) 2007-01-19 2013-02-14 Intercept Pharmaceuticals, Inc. 23-substituted bile acids as TGR5 modulators and methods of use thereof
US8338628B2 (en) * 2007-08-28 2012-12-25 City Of Hope Method of synthesizing alkylated bile acid derivatives
CA2732323C (en) 2008-07-30 2017-06-27 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
JP5535233B2 (en) 2008-11-19 2014-07-02 インターセプト ファーマシューティカルズ， インコーポレイテッド TGR5 modulator and method of using the same
CA3047776C (en) 2012-06-19 2022-10-18 Intercept Pharmaceuticals, Inc. Preparation, uses and solid forms of obeticholic acid
US9982008B2 (en) 2012-06-19 2018-05-29 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
PE20160665A1 (en) * 2013-05-14 2016-08-07 Intercept Pharmaceuticals Inc 11-HYDROXYL DERIVATIVES OF BILE ACIDS AND CONJUGATES OF AMINO ACIDS THEREOF AS MODULATORS OF THE FARNESOID X RECEPTOR
CN105764569B (en) 2013-09-11 2019-09-13 国家医疗保健研究所 Treat hepatitis b virus infected method and pharmaceutical composition
CN104672290B (en) * 2015-01-05 2017-06-06 北京普禄德医药科技有限公司 A kind of medicine of disease for preventing or treating FXR mediations and its production and use
US20200054589A1 (en) 2017-02-21 2020-02-20 Genfit Combination of a ppar agonist with a fxr agonist
US20210085662A1 (en) 2017-03-30 2021-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
EP3705487B1 (en) * 2017-11-02 2022-10-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
CN114173784B (en) 2019-07-18 2023-12-01 埃尼奥制药公司 Method for reducing side effects of interferon
EP4090327A1 (en) 2020-01-15 2022-11-23 Institut National de la Santé et de la Recherche Médicale (INSERM) Use of fxr agonists for treating an infection by hepatitis d virus
CA3204800A1 (en) 2021-01-14 2022-07-21 Raphael Darteil Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1223313B (en) * 1987-10-20 1990-09-19 Gipharmex Spa BILIARY ACID DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
IT1229570B (en) * 1989-04-17 1991-09-04 Giuliani Spa FLUORATED DERIVATIVES OF BILIARY ACIDS, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
CA2440680C (en) * 2001-03-12 2010-06-01 Roberto Pellicciari Steroids as agonists for fxr

Also Published As

Publication number Publication date
ITMI20021532A1 (en) 2004-01-12
WO2004007521A3 (en) 2004-04-01
WO2004007521A2 (en) 2004-01-22
AU2003250935A1 (en) 2004-02-02

Similar Documents

Publication Publication Date Title
AU2003250935A8 (en) Bile acid derivatives as agonists of the farnesoid x receptor
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
AU2003290700A1 (en) Farnesoid x receptor agonists
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
HK1084043A1 (en) Derivatives of aryl-quinazoline/aryl-2amino-phenylmethanone which promote the release of parathyroidhormone
IL175349A0 (en) 2-halogen-6-alkyl-phenyl substituted tetramic acid derivatives
AU2003228485A1 (en) Farnesoid x-activated receptor agonists
GB0315870D0 (en) Heterocyclic derivatives
PL377609A1 (en) Indazole derivatives as crf antagonists
AU2003275838A8 (en) Pyrrolidin-2-on derivatives as ep4 receptor agonists
AU2003256922A8 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
AU2003301129A1 (en) Steroid compositions for intraocular use
AU2003231805A8 (en) Purine derivatives as liver x receptor agonists
PL373624A1 (en) 4-[7-halo-2-quino (xa-) linyloxy]phenoxy-propionic acid derivatives as antineoplastic agents
AU2003301216A8 (en) Novel use of liver x receptor agonists
PL377504A1 (en) Arylene-carboxylic acid (2-amino-phenyl)-amide derivatives as pharmaceutical agents
PL1751095T3 (en) Substituted cyclohexylcarboxylic acid derivatives
EP1389200A4 (en) Substituted n-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
HK1076821A1 (en) Branched polyamine steroid derivatives
IL165137A0 (en) Process for the preparation of thioalkylamine derivatives
AU2003273169A1 (en) 7-phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents
AU2003257289A8 (en) Pharmaceutical compositions for penis enlargement
SG107315A1 (en) Use of conjugated linoleic acid derivatives
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
AU2003286316A1 (en) 5-aminophenanthridine derivatives as npy-5 antagonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase